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ABSTRACT	
	
Objective:	In	rheumatoid	arthritis	(RA),	magnetic	resonance	imaging	(MRI)	provides	earlier	
detection	of	structural	damage	than	radiography	(X-ray)	and	more	sensitive	detection	of	
intra-articular	inflammation	than	clinical	examination.	This	analysis	was	designed	to	evaluate	
the	ability	of	early	MRI	findings	to	predict	subsequent	structural	damage	by	X-ray.	
Methods:	Pooled	data	from	4	randomized	controlled	trials	(RCTs)	involving	1022	RA	hands	and	
wrists	in	early	and	established	RA	were	analyzed.	X-rays	were	scored	using	van	der	Heijde-	or	
Genant-modified	Sharp	methods.	MRIs	were	scored	using	Outcome	Measures	in	Rheumatology	
(OMERACT)	RA	MRI	Score	(RAMRIS).	Data	were	analyzed	at	the	patient	level	using	multivariable	
logistic	regression	and	Receiver	Operating	Characteristic	(ROC)	curve	analyses.	
Results:	Progression	of	MRI	erosion	scores	at	Weeks	12	and	24	predicted	progression	of	X-ray	
erosions	at	Weeks	24	and	52,	with	areas	under	the	curve	(AUCs)	of	0.64	and	0.74,	respectively.	
Twelve-	and	24-week	changes	in	MRI	osteitis	scores	were	similarly	predictive	of	24-	and	52-week	
X-ray	erosion	progression;	pooled	AUCs	0.78	and	0.77,	respectively.	MRI	changes	in	synovitis	at	
Weeks	12	and	24	also	predicted	progression	of	X-ray	joint	damage	(erosion	and	joint-space	
narrowing)	at	Weeks	24	and	52	(AUCs	=	0.72	and	0.65,	respectively).	
Conclusion:	Early	changes	in	joint	damage	and	inflammation	detected	with	MRI	predict	changes	
in	joint	damage	evident	on	subsequent	X-rays.	These	findings	support	the	use	of	MRI	as	a	valid	
method	for	monitoring	structural	damage	in	short-duration	RCTs.	
Key	words:	Magnetic	Resonance	Imaging,	Rheumatoid	Arthritis,	Outcomes	research	
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INTRODUCTION	
Radiography	has	been	the	standard	for	assessing	structural	damage	in	RA	RCTs	for	many	years.	
Recently,	however,	discriminating	differences	in	the	rates	of	progression	of	X-ray	damage	
between	treatment	arms	has	become	more	challenging.	The	most	important	reason	for	this	
has	been	recognition	that	exposing	subjects	with	active	RA	to	placebo	for	longer	than	12	weeks	
is	unethical.	1	Accordingly,	current	US	FDA	guidance	states	that	trials	of	>12	weeks	should	
include	an	active	comparator	as	the	control	or	make	provisions	for	rescue	therapy.2		This	poses	
a	major	obstacle	to	using	X-ray	in	RCTs,	because	24	weeks	is	typically	necessary	for	
radiographic	demonstration	of	inhibition	of	structural	progression,	and	longer	treatment	
duration	and	larger	numbers	to	resolve	differences	between	active	comparators.	A	method	
that	more	reliably	detects	structural	progression	within	a	3	month	time	frame	would	therefore	
be	helpful.		
MRI	has	demonstrated	criterion	validity	for	osteitis	and	synovitis	with	histology,	and	construct	
validity	for	erosions	when	compared	to	computed	tomography.	3,	4		Numerous	studies	have	
demonstrated	MRI	to	be	more	sensitive	than	X-ray	for	detecting	joint	damage,	and	to	detect	
synovitis	and	osteitis	more	sensitively	than	clinical	examination	does.	Consequently,	there	has	
been	a	rapid	increase	in	the	use	of	MRI	in	RA	RCTs	over	the	past	decade.	4		A	recent	report	by	
the	Imaging	Subcommittee	of	the	ACR	Clinical	Trials	Task	Force	4	concluded	that	MRI	met	the	
OMERACT	validation	filter	for	“truth,	discrimination	and	feasibility.”	5,6	It	concluded	that	
“among	all	of	the	currently	available	imaging	modalities	that	have	been	validated	with	
supportive	data,	MRI	best	serves	the	purpose	of	achieving	sensitive	ascertainment	of	structural	
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damage	in	RCTs	while	also	providing	objective	measures	of	inflammatory	predictors	of	
damage,”.	The	report	proposed	analyzing	recently	completed	RCTs	that	included	both	MRI	and	
X-ray	assessments	to	evaluate	the	predictive	validity	of	MRI.	
Accordingly,	under	the	auspices	of	OMERACT,	a	task	force	of	the	members	of	the	Imaging	
Subcommittee	of	the	ACR	Clinical	Trials	Task	Force	obtained	and	pooled	data	from	four	RCTs	
that	included	both	serial	MRIs	(baseline	to	12	and/or	24	weeks)	and	X-rays	(baseline	to	24	
and/or	52	weeks)	to	evaluate	the	ability	of	MRI	to	predict	long-term	structural	damage	on	X-
rays	at	the	individual	patient	level	using	a	statistical	meta-analysis	approach.	The	overall	
prediction	performance	for	the	patient	population	was	evaluated	by	ROC	analysis.	
METHODS	
Data	from	4	placebo	RCTs	(Table	1)	in	active	RA	patients	were	included,	in	which	1022	hands	
and	wrists	had	both	MRI	and	X-ray	erosion	scores	at	baseline.	Information	included	RCT	design,	
MRI	protocols	and	baseline	MRI	and	X-ray	scores.	Individual	patient	identification,	study	
identification,	and	treatment	assignments	remained	blinded.	To	maintain	confidentiality,	the	
RCTs	are	referred	to	as	Trials	A-D.	Measurement	schedules	are	summarized	in	Table	1.	Additional	
methodological	details	are	provided	in	online	Supplementary	Information.		Multivariable	logistic	
regression	analysis	coupled	with	a	nonparametric	spline	method	was	performed	to	assess	the	
ability	of:	
(1) Baseline	MRI	erosion	scores	and	changes	from	baseline	to	Weeks	12	or	24	to	predict	X-ray	
progression	(increase	>0.5	in	X-ray	erosion	scores	from	baseline	to	Weeks	24	or	52).		
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(2) Baseline	MRI	osteitis	scores	and	changes	from	baseline	to	Weeks	12	or	24	to	predict	X-ray	
progression	(increase	>0.5	in	X-ray	erosion	scores	from	baseline	to	Weeks	24	or	52).		
(3) Baseline	MRI	synovitis	scores	and	changes	from	baseline	to	Weeks	12	or	24	to	predict	X-ray	
progression	(increases	>0.5	in	X-ray	Total	modified	Sharp	Scores	from	baseline	to	Weeks	24	or	
52).		
Specifically,	the	regression	included	three	dummy	variables	indicating	the	four	studies	and	five	
basis	functions,	𝑀𝑅𝐼!,Δ!"# ,Δ!"#! , Δ!"# − 0.5 !, Δ!"# !	and	 Δ!"# + 0.5 !,	as	independent	
variables,	where	𝑀𝑅𝐼!	and	Δ!"#  were	the	baseline	MRI	measure	and	short-term	change	in	MRI	
measure	(erosion,	osteitis	or	synovitis	score),	respectively	and	𝑥!	represented	the	positive	part	of	𝑥.		The	dummy	variables	representing	four	RCTs	accounted	for	different	progression	rates	among	
patients	enrolled	in	each	trial.		The	association	between	baseline	and	short-term	changes	in	MRI	
and	longer-term	X-ray	progression	was	characterized	by	the	estimated	linear	combination	of	the	
aforementioned	basis	functions.		The	ROC	curves	of	the	estimated	linear	combination	and	AUC	
measurements	were	derived	to	determine	the	discriminative	power	of	early	changes	in	MRI	
endpoints	for	detecting	subsequent	structural	progression	by	X-ray	(AUC	0.5-0.7	=	poor,	0.7-0.8	=	
acceptable,	0.8-0.9	=	excellent,	>0.9	=	outstanding	discrimination	7).		All	statistical	analysis	were	
performed	using	R-3.2.2	(The	R	foundation	of	Statistical	Computing).	
RESULTS	
Table	2	shows	baseline	X-ray	and	MRI	scores	of	included	patients	from	the	four	trials.	The	
association	between	12-week	change	in	MRI	erosion	score	and	24-week	change	in	X-ray	erosion	
score	was	examined	in	trials	A,	B	and	C;	week-12	MRI	data	was	not	available	for	trial	D.	After	
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excluding	patients	with	missing	information,	the	proportions	of	patients	with	X-ray	erosion	
progression	>0.5	Sharp	units	at	Week	24	in	trials	A,	B,	C	and	the	pooled	cohort	were	5.7%	
(10/166),	7.5%	(69/855),	4.0%	(22/534)	and	6.1%	(101/1555),	respectively.	ROC	curve	analysis	of	
the	prediction	of	X-ray	progression	at	Week	24	based	on	a	logistic	regression	model	of	baseline	
MRI	erosion	score	and	12-week	MRI	progression	in	erosion	score	showed	an	AUC	of	0.64	(95%	
Confidence	Intervals	(CI)	=0.54-0.75)	(Fig.	1).	Since	we	were	interested	in	the	predictive	value	of	
MRI	beyond	that	due	to	varying	progression	rates	across	trials,	we	also	performed	a	logistic	
regression	with	trial	indicators	as	the	only	independent	variables,	and	the	AUC	for	this	was	only	
0.51	(95%	CI=0.41-0.62).	Adjusted	for	trial	indicators,	the	predictiveness	of	12-week	MRI	changes	
combined	with	baseline	MRI	erosion	scores	was	statistically	significantly	greater	than	that	using	
the	trial	indicator	alone	(p=0.031).	Results	by	trial	are	shown	in	Table	3.		
The	association	between	24-week	change	in	MRI	erosion	score	and	52-week	change	in	X-ray	
erosion	score	was	examined	using	data	from	trials	B,	C	and	D,	as	trial	A	did	not	include	Week	52	
X-ray	data	(Table	1).	The	proportions	of	patients	with	X-ray	erosion	progression	at	Week	52	were	
9.0%	(79/799),	4.3%	(22/494),	7.8%	(31/364)	and	7.4%	(132/1657)	in	trials	B,	C,	D	and	the	pooled	
cohort,	respectively.	The	AUC	for	predicting	X-ray	erosion	progression	at	Week	52	based	on	MRI	
erosion	scores	at	baseline	and	change	at	Week	24	was	0.74	(95%	CI=0.66-0.82)	(Fig.	1),	which	is	
considered	acceptable	7	If	the	logistic	regression	model	considered	only	the	trial	as	a	variable,	the	
AUC	was	poor	(0.55;	95%	CI=0.48-0.62).	Adjusted	for	the	trials,	the	predictiveness	of	24-week	
change	combined	with	baseline	MRI	erosion	scores	was	highly	statistically	significantly	greater	
than	that	using	the	trial	indicator	alone	(p<0.001).	Results	by	trial	are	shown	in	Table	3.		
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The	association	between	12-week	change	in	MRI	osteitis	score	and	24-week	change	in	X-ray	
erosion	score	was	examined	in	trials	A,	B	and	C;	trial	D	did	not	include	osteitis	scores.	ROC	
analysis	of	the	prediction	of	X-ray	erosion	progression	at	Week	24	based	on	12-week	MRI	
progression	in	osteitis	showed	a	near	excellent	AUC	of	0.78	(95%	CI=0.70-0.86)	(Fig.	1).	As	a	
reference,	if	only	trial	indicators	were	included	as	the	predictors,	the	AUC	of	the	logistic	
regression	was	very	poor	(0.51;	95%	CI=0.41-0.62)	suggesting	that	trial	indicators	alone	are	not	
predictive	of	X-ray	erosion	progression.		Adjusted	for	the	trials,	the	predictiveness	of	12-week	
change	and	baseline	MRI	osteitis	scores	was	highly	statistically	significantly	greater	than	that	
using	the	trial	indicator	alone	(p<0.001).		The	association	between	24-week	change	in	MRI	osteitis	
score	and	52-week	change	in	X-ray	erosion	score	was	examined	in	trials	B	and	C;	trial	A	lacked	
Week	52	X-ray	data	and	trial	D	lacked	osteitis	scores.	The	AUC	for	predicting	X-ray	erosion	
progression	based	on	MRI	osteitis	scores	at	baseline	and	for	change	at	Week	24	was	also	near	
excellent	(0.77;	95%	CI=0.66-0.88)	(Fig.	1)	and	again	significantly	greater	(p<0.001)	than	that	
observed	if	only	the	trial	indicator	was	considered	in	the	regression	model	(0.57;	95%	CI=0.47-
0.67).	
The	association	between	12-week	change	in	MRI	synovitis	score	and	24-week	change	in	X-ray	
Total	modified	Sharp	score	was	examined	in	trials	A,	B	and	C,	as	trial	D	did	not	include	synovitis	
scores.	At	week	24,	9.7%(17/159),	9.7%(90/834),	8.6%(48/508)	and	9.4%(155/1501)	of	hands	
demonstrated	X-ray	progression	in	trials	A,	B,	C	and	the	combined	cohort,	respectively.	The	AUC	
for	predicting	X-ray	progression	by	MRI	was	acceptable	(0.72;	95%	CI=0.64-0.81)	(Fig.	1),	and	
significantly	greater	(p<0.001)	than	that	observed	if	only	the	trial	was	considered	(0.55;	95%	
CI=0.47-0.63).	
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The	association	between	24-week	change	in	MRI	synovitis	score	and	52-week	change	in	X-ray	
Total	modified	Sharp	Score	was	examined	in	trials	B	and	C;	trial	A	did	not	include	Week	52	X-ray	
data	and	trial	D	did	not	include	synovitis	scores.	At	week	52,	12.0%	(105/773),	9.7%(50/466)	and	
11.1%(155/1239)	of	hands	demonstrated	X-ray	progression	in	trials	B,	C	and	the	pooled	cohort,	
respectively.	The	AUC	of	the	ROC	curve	of	MRI	scores	at	baseline,	week-24	MRI	changes	and	trial	
data	predicting	X-ray	progression	at	52	weeks	was	0.65	(95%	CI=0.55-0.75)	(Fig.	1),	compared	to	
0.51	(95%	CI=0.42-0.59,	p=0.063)	if	only	the	trial	was	considered	in	the	regression	model.	
DISCUSSION	
This	analysis	shows	that	changes	in	joint	damage	and	inflammation	detected	with	MRI	as	early	
as	12	weeks	predict	changes	in	joint	damage	evident	on	subsequent	X-rays.	The	current	analysis	
of	pooled	data	from	four	RCTs	that	included	both	MRI	and	X-ray	demonstrated	that	progression	
of	MRI	erosion	scores	at	Weeks	12	and	24	predict	progression	of	X-ray	erosions	at	Weeks	24	and	
52.	Twelve-	and	24-week	changes	in	MRI	osteitis	scores	and	synovitis	scores	were	similarly	
predictive	of	24-week	and	52-week	X-ray	erosion	progression.	These	findings	corroborate	those	
of	Baker,	et	al.	8	who	further	showed	that	MRI	could	allow	a	large	reduction	in	the	number	of	
patients	needed	to	assess	structural	damage	in	RA	RCTs	relative	to	that	required	with	X-ray;	9		
MRI	has	been	used	in	13	multicenter,	placebo	RCTs	reported	to	date,	10	11	12	13	14	15	16	17	18	19	20	21	22	
involving	ten	different	biologic	therapies.	Nine	RCTs	11	13	14	15	16	17	18	21	22	included	follow-up	
intervals	≤12-16	weeks,	and	in	seven	of	the	nine,	MRI	demonstrated	statistically	significant	
inhibition	of	progression	of	bone	erosions	with	active	treatment	compared	to	placebo	within	that	
timeframe	14	15	17	18	or	showed	a	lack	of	inhibition	consistent	with	later	X-ray	data	within	the	trial	16	
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22	or	in	subsequent	trials.	23		Two	of	the	nine	RCTs	were	underpowered,	but	did	show	numerical	
suppression	of	erosion	progression	on	early	MRI	(one	RCT	included	only	20-21	patients	per	arm,	
and	in	contrast	to	the	other	RCTs,	used	only	a	single	reader;	13	the	second	RCT	included	28-35	
patients	per	arm,	and	showed	numerical	suppression	of	MRI	erosion	relative	to	placebo	at	4	and	
12	weeks	and	statistically	significant	suppression	by	24	weeks	21).	
Two	of	the	nine	RCTs	discussed	above	17	21	and	an	active-comparator	trial	24	included	MRI	follow-
up	intervals	of	4	weeks	or	less.	Two	of	these	trials	demonstrated	statistically	significant	
suppression	of	synovitis	and	osteitis	with	MRI	after	only	2	weeks	of	active	therapy,	using	30-32	24	
and	30-31	17	patients	per	arm,	respectively.	Both	trials	also	showed	inhibition	of	erosion	with	MRI	
at	later	time	points.	The	third	study	21	was	underpowered	for	RAMRIS,	as	noted	above,	but	
showed	numerical	decreases	in	osteitis,	synovitis	as	well	as	in	erosion	progression	with	treatment	
compared	to	placebo	at	4	weeks.	
There	were	a	number	of	limitations	to	this	analysis.	Some	trial	datasets	could	not	be	included	
because	they	did	not	have	earlier	MRI	followed	by	later	X-ray	outcomes.	Of	the	three	studies	
referred	to	above	with	MRI	follow-up	intervals	<12	weeks,	one	17	did	not	include	X-ray	and	the	
other	24	used	0.2T	rather	than	1.5T	MRI,	so	we	were	unable	to	examine	whether	very	early	MRI	
inflammation	measures	would	be	predictive	of	X-ray	structural	outcomes.	Another	limitation	was	
that	all	but	one	of	the	four	datasets	rescued	placebo	patients	with	active	therapy	by	24	weeks,	
confounding	analyses	based	on	X-ray	data	over	longer	time	intervals.	This	is,	however,	an	issue	
for	all	modern	RCTs	given	current	restrictions	on	the	duration	of	placebo	treatment.	If	by	24	
weeks	the	most	rapidly	progressing	patients	in	the	placebo	arm	of	a	trial	have	received	rescue	
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treatment,	X-rays	acquired	at	24	weeks	will	underestimate	the	true	placebo	progression	rate	and	
thus	the	effect	size	of	treatment.	This	limitation	highlights	why	a	method,	such	as	MRI,	that	is	
sensitive	enough	to	discriminate	treatment	effect	within	only	12	weeks,	i.e.,	before	rescue	
treatment,	is	needed.	Similarly	in	this	analysis,	24-week	X-rays	of	patients	rescued	prior	to	24	
weeks	will	categorize	some	12-week	MRI	progressors	incorrectly	as	false	positives,	and	artificially	
reduce	the	AUC.	Which	patients	received	rescue	therapy	was	known	in	two	of	the	four	RCTs	
analyzed.	However,	removing	these	patients	from	analysis	in	one	trial	(A)	did	not	significantly	
change	the	results	(data	not	shown).		
While	the	nonparametric	spline	fitting	method	used	in	this	analysis	is	a	flexible	nonparametric	
approach,	the	resulting	model	may	not	have	been	optimal,	and	higher	AUCs	for	the	MRI	
measures	could	potentially	have	been	attained	by	including,	for	example,	additional	information	
about	the	individual	patients	and	more	flexible	basis	functions	of	the	MRI	measures.		
Nevertheless,	the	estimated	predictive	value	of	MRI	measures	summarized	by	the	AUCs	of	the	
ROC	curve	offers	a	conservative	estimate	of	the	true	predictive	value.		
Lastly,	we	did	not	have	access	to	MRI	cartilage	loss	or	MRI	joint-space	narrowing	scores	for	any	of	
the	trials	included	in	this	analysis.	However,	the	validity	of	assessing	cartilage	loss	and	joint-space	
narrowing	with	MRI	has	been	well	documented,	25	26	27	28	and	six	RA	RCTs	have	included	MRI	
scoring	of	cartilage	loss	14	17	18	22	29	or	joint-space	narrowing;	20	all	have	demonstrated	good	
responsiveness.	
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In	summary,	on	the	basis	of	this	analysis	and	previous	studies,	we	conclude	that	MRI	can	detect	
progression	of	structural	damage	in	RA	RCTs	as	soon	as	3	months	and	discriminate	inhibition	of	
progression	of	joint	damage	within	this	timeframe	in	placebo-controlled	trials	with	approximately	
30-70	patients	per	treatment	arm.	We	therefore	recommend	MRI	as	an	imaging	modality	to	
assess	inflammation	and	joint	damage	in	short-duration	RCTs	in	RA	to	reduce	the	number	of	
patients	and	trial	duration	required	to	demonstrate	inhibition	of	structural	damage.		
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Tables	
	
Table	1.	Imaging	schedule	for	included	trials	
Trial	 Baseline		 Week	12	 Week	24	 Week	52	 Rescue	
treatment	
information	
A	 MRI,	X-ray	 MRI	 MRI,	X-ray	 N/A	 Available	
B	 MRI,	X-ray	 MRI	 MRI,	X-ray	 MRI,	X-ray	 N/A	
C	 MRI,	X-ray	 MRI	 MRI,	X-ray	 MRI,	X-ray	 N/A	
D	 MRI,	X-ray	 N/A	 MRI*,	X-ray	 X-ray	 Available	
*	Only	erosion	scores	available;	N/A,	not	available	
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Table	2.	Baseline	X-ray	and	MRI	scores	
Trial X-ray		
Erosion 
X-ray		
Total	
MRI	
Erosion		
MRI		
Osteitis		
MRI		
Synovitis		
A	
(n	=	185)	
3.25	(3.68),	
2.00	(0.75,	4.00)	
5.36(6.52),	
3.00	(1.00,	7.00)	
13.63(12.44),	
10.00	(4.50,	20.00)	
7.23(8.06),	
4.50	(1.00,	10.50)	
7.82(4.60),	
7.00	(4.50,	11.00)	
B	
(n	=	1272)	
3.50	(6.29),	
1.00	(0.50,	3.50)	
6.52(12.40),	
1.50	(0.50,	6.00)	
22.17(22.96),	
14.50	(10.50,	23.50)	
10.02(11.21),	
6.00	(2.50,	13.50)	
10.14(6.80),	
9.00	(5.00,	13.50)	
C	
(n	=	888)	
5.44(8.97),	
1.50	(0.00,	7.00) 
12.06(18.07),	
3.00	(0.50,	16.50)	
23.50(24.71),	
14.75	(6.88,	30.12)	
4.98(7.54),	
2.00	(0.00,	6.63)	
7.15(5.26),	
6.50	(3.50,	9.50)	
D	
(n	=	450)	
5.90(7.07),	
3.50	(1.00,	8.50) 
12.42(15.19),	
6.50	(1.50,	18.50)	
18.72(18.17),	
12.50	(5.25,	26.31)	
N/A	 N/A	
Pooled	
(n	=	2795)	
4.47(7.17),	
1.50	(0.50,	3.25) 
9.05(14.62),	
2.50	(0.50,	11.00)	
19.42(20.03),	
13.12	(6.50,	25.00)	
7.76(9.59),	
4.25	(1.00,	11.00)	
8.59(5.92),	
7.50	(4.50,	11.50)	
Values	are	mean	(standard	deviation),	median	(upper,	lower	quartiles);	N/A,	not	available;	n,	all	
hands	including	those	with	missing	measurements	at	baseline	or	follow-up	
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Table	3.	AUC	(95%	CI)	values	based	on	ROC	curve	analysis	for	individual	trials	
	 Trial	A	 Trial	B	 Trial	C	 Trial	D	
12-week	MRI	
erosion	vs.	24-
week	X-ray	
erosion	
0.60	(0.44-0.77)	
n	=	169	hands	
0.67	(0.46-0.88)	
n	=	218	hands	
0.65	(0.51-0.78)	
n	=	153	hands	
N/A	
24-week	MRI	
erosion	vs.	52-
week	X-ray	
erosion	
0.77	(0.62-0.93)	
n	=	208	hands	
N/A	 0.70	(0.44-0.95)	
n	=	148	hands	
0.73	(0.62-0.85)	
n	=	387	hands	
12-week	MRI	
osteitis	vs.	24-
week	X-ray	
erosion	
0.78	(0.63-0.93)	
n	=	169	hands	
0.82	(0.71-0.94)	
n	=	218	hands	
0.51	(0.24-0.78)	
n	=	153	hands	
N/A	
24-week	MRI	
osteitis	vs.	52-
week	X-ray	
erosion	
N/A	 0.77	(0.64-0.90)	
n	=	208	hands	
0.67	(0.38-0.96)	
n	=	148	hands	
N/A	
12-week	MRI	
synovitis	vs.	24-
week	X-ray	total	
0.70	(0.56-0.84)	
n	=	169	hands	
0.69	(0.54-0.84)	
n	=	218	hands	
0.76	(0.65-0.88)	
n	=	153	hands	
N/A	
24-week	MRI	
synovitis	vs.52-
week	X-ray	total	
N/A	 0.66	(0.52-0.80)	
n	=	208	hands	
0.65	(0.50-0.79)	
n	=	148	hands	
N/A	
N/A,	not	available. 
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FIGURE	LEGENDS	
	
Figure	1.	ROC	curves	for	predicting	24-week	(A,	C,	E)	and	52-week	(B,	D,	F)	change	in	X-ray	
erosion	(A-D)	or	Total	modified	Sharp	(E,	F)	scores	using	12-week	(A,	C,	E)	or	24-week	(B,	D,	F)	
MRI	changes	in	erosion	(A,	B),	osteitis	(C,	D)	and	synovitis	(E,	F)	scores	based	on	pooled	trial	data.	
Red	line:	only	trial	information;	black	line:	trial	and	MRI	information	(baseline	scores	and	12-week	
or	24-week	change	scores),	grey	line,	theoretical	absence	of	discrimination.	
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